Randomized controlled study of amantadine combined with dalingfu in the treatment of patients with Parkinson's disease

doi:10.3760/cma.j.issn.1007-1245.2021.06.024

Abstract

Abstract: Objective To analyze the effect of amantadine combined with dalingfu on mental state and cognitive function of patients with Parkinson's disease. Methods A total of 122 patients with Parkinson's disease who were treated in our hospital from January 2017 to July 2019 were selected and were divided into the observation group (oral amantadine and dalingfu) and the control group (oral amantadine and levodopaand benserazide hydrochloride) by the random number table method. The clinical efficacy, mental status, cognitive function, symptom score, serum index, and adverse reactions of the two groups were observed. Results The effective rate of the observation group was 93.44% (57/61), which was higher than 78.69% (48/61) of the control group (P<0.05). After treatment, the MMSE score and MoCA score of the observation group were higher than those before treatment and those of the control group, and the UPDRS score was lower than that before treatment and that of the control group (all P<0.05). After treatment, serum levels of GSH-Px, SOD, DA, 5-HT, NE, and BDNF in the observation group were higher than those before treatment and those in the control group, and serum levels of MDA, IL-6, and IL-1β were lower than those before treatment and those in the control group (all P<0.05). During the treatment period, the total incidence of complications in the observation group was 11.48% (7/61), and 8.20% (5/61) in the control group, without statistically significant difference (P>0.05). Conclusion Amantadine combined with Dalingfu can effectively improve the cognitive function and mental state of patients with Parkinson's disease, and its effect may be related to the restoration of serum neurotransmitter levels.

Key words: Parkinson's disease, Cognitive impairment, Amantadine, Dalingfu

摘要： 目的分析金刚烷胺联合达灵复对帕金森病患者精神状态与认知功能的影响。方法选取2017年1月至2019年7月于本院治疗的帕金森病患者122例,随机数字表法将患者分为观察组(口服金刚烷胺联合达灵复)、对照组(口服金刚烷胺与多巴丝肼)。观察两组患者临床疗效、精神状态、认知功能、症状评分、血清指标及不良反应情况。结果观察组有效率为93.44%(57/61),高于对照组的78.69%(48/61)(P<0.05)。治疗后观察组患者MMSE评分、MoCA评分较治疗前、对照组升高,UPDRS评分较治疗前、对照组降低(均P<0.05)。观察组治疗后血清GSH-Px、SOD、DA、5-HT、NE、BDNF含量较治疗前、对照组升高,血清MDA、IL-6、IL-1β含量较治疗前、对照组降低(均P<0.05)。治疗期间观察组并发症总发生率11.48%(7/61),对照组总发生率8.20%(5/61),差异无统计学意义(P>0.05)。结论金刚烷胺联合达灵复可有效改善帕金森病患者认知功能与精神状态,其作用可能与恢复血清神经递质含量等有关。

关键词: 帕金森病, 认知功能障碍, 金刚烷胺, 达灵复

Shao Keke, Ru Wenwen. Randomized controlled study of amantadine combined with dalingfu in the treatment of patients with Parkinson's disease[J]. International Medicine and Health Guidance News, 2021, 27(6): 881-884.

邵可可, 汝文文. 金刚烷胺联合达灵复治疗帕金森病患者的随机对照研究[J]. 国际医药卫生导报, 2021, 27(6): 881-884.

References

[1] 仇成轩,闫中瑞,杜怡峰.延迟老年痴呆症发病的人群干预策略[J].中华行为医学与脑科学杂志,2017,26(6):501-506. DOI:10.3760/cma.j.issn.1674-6554.2017.06.005.
[2] deVries T, Dentiste A, Di Lea C, et al. Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets[J]. CNS Drugs, 2019, 33(8):783-789. DOI: 10.1007/s40263-019- 00651-1.
[3] Zhang J, Tan H, Jiang W, et al.Amantadine alleviates postoperative cognitive dysfunction possibly by increasing glial cell line-derived neurotrophic factor in rats[J]. Anesthesiology, 2014, 121(4):773-785. DOI: 10.1097/ALN.0000000000000352.
[4] 伍倩戎,黄玮,唐厚梅,等.高压氧联合盐酸美金刚治疗老年痴呆症患者的临床疗效[J].中华航海医学与高气压医学杂志,2019,26(3):183-186. DOI:10.3760/cma.j.issn.1009- 6906.2019.03.004.
[5] 卢靖,朱余兵,潘希丁.2015—2017年南京市第一医院抗帕金森病药物的使用情况分析[J].现代药物与临床,2019,34(9):2817-2821. DOI:10.7501/j.issn.1674-5515. 2019. 09.054.
[6] Mura E, Pistoia F, Sara M, et al.Pharmacological modulation of the state of awareness in patients with disorders of consciousness: an overview[J]. Curr Pharm Des, 2014, 20(26):4121-4139.
[7] 中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南(第三版)[J].中华神经科杂志,2014,(6):428-433. DOI:10.3760/cma.j.issn.1006-7876. 2014. 06.017.
[8] 曲艳,李晓红,孙亚南,等.汉化版MDS-UPDRS与传统UPDRS评测帕金森病的比较分析[J].中国康复理论与实践,2019,25(8):936-939. DOI:10.3969/j.issn.1006?9771.2019. 08.010.
[9] 周小炫,谢敏,陶静,等.简易智能精神状态检查量表的研究和应用[J].中国康复医学杂志,2016,31(6):694-696,706. DOI:10.3969/j.issn.1001-1242.2016.06.019.
[10] 孟晓梅,于逢春,尹静,等.蒙特利尔认知评估量表用于轻度认知功能障碍患者评估的初步研究[J].中华老年心脑血管病杂志,2012,14(11):1173-1175. DOI:10.3969/j.issn.1009-0126.2012.11.016.
[11] 王家良, 王滨有. 临床流行病学学习指导与习题集[M]. 北京:人民卫生出版社, 2008:105-109.
[12] Elmer LW, Juncos JL, Singer C, et al.Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease[J]. CNS Drugs, 2018, 32(4):387-398. DOI: 10.1007/s40263-018-0498-4.
[13] Levite M.Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases[J]. Acta Physiol (Oxf), 2016, 216(1):42-89. DOI: 10.1111/apha.12476.
[14] 王冰,赵泐,李晓燕,等.丁苯酞软胶囊改善帕金森痴呆患者认知功能和日常生活能力的效果[J].国际精神病学杂志,2017,44(6):1060-1063. DOI: 10.13479/j.cnki.jip.2017. 06.030.
[15] Cannas A, Meloni M, Mascia MM, et al.Priapism and Hypersexuality Associated With Rotigotine in an Elderly Parkinsonian Patient: A Case Report[J]. Clin Neuropharmacol, 2016, 39(3):162-163. DOI: 10.1097/WNF.0000000000000157.
[16] Meng F, Dai E, Yu X, et al.Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease[J]. J R Soc Interface, 2013, 11(92):20131057. DOI: 10.1098/rsif.2013.1057.
[17] Lee PY, Tu HP, Lin CP, et al.Amantadine Use as a Risk Factor for Corneal Edema: A Nationwide Cohort Study in Taiwan[J]. Am J Ophthalmol, 2016, 171:122-129. DOI: 10.1016/j.ajo.2016.08.034.
[18] 岳术义,冀学红,李瑞莲,等.多巴丝肼片治疗帕金森病伴疼痛的疗效及对认知功能的影响[J].中国药业,2019,28(5):76-78. DOI:10.3969/j.issn.1006-4931.2019.05.026.